Egrifta Approved for HIV-Related Lipodystrophy
Links shared publicly online about this topic.
- 734total visits
Egrifta Approved for HIV-Related Lipodystrophy
View full resource at webmd.com
Tags: HIV, AIDS, HIV Medication, STD, Fat, Drug, FDA
Most Recently Shared on November 12, 2010 at 1:59 am By:
Egrifta OK’d for Excess Fat Due to AIDS Drugs: The FDA has approved Egrifta, administered by daily injection, ... http://bit.ly/aaSmQc
Also Shared By:
FDA approves tesamorelin for HIV-related lipodystr... [Am J Health Syst Pharm. 2010] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on December 3, 2010 at 9:05 pm By:
FDA approves tesamorelin for HIV-related lipodystrophy.: Authors: Traynor K PMID: 21115997 [PubMed - in... http://bit.ly/dV0LV0
Tesamorelin Is Approved - The Body
thebody.com — “This just in from the FDA: The U.S. Food and Drug Administration today approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a ...” View full resource at thebody.com
Most Recently Shared on November 15, 2010 at 6:01 pm By:
HIV doc Paul Sax, M.D., on questions that remain following approval of Egrifta (tesamorelin) for treating belly fat: http://bit.ly/d6N6u9
Medicine and Technology [part of HCPLive]: FDA approves Egrifta to treat Lipodystrophy in HIV patients
medicineandtechnology.com — “Medicine and Technology [part of HCPLive]: FDA approves Egrifta to treat Lipodystrophy in HIV patients” View full resource at medicineandtechnology.com
Most Recently Shared on November 12, 2010 at 2:56 am By:
Joseph Kim, MD, MPH Physician and Doctor
FDA approves Egrifta to treat Lipodystrophy in HIV patients http://goo.gl/fb/WG0Sx
Egrifta OK--™d for Excess Fat Due to AIDS Drugs - QualityPoint Technologies
qualitypointtech.net — “The FDA has approved Egrifta, administered by daily injection, for the treatment of HIV lipodystrophy -- fat accumulation that is a side effect of AIDS drugs. (Source: WebMD Health)MedWorm Message: Register forMedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.” View full resource at qualitypointtech.net
Most Recently Shared on November 12, 2010 at 1:34 am By:
Egrifta OK’d for Excess Fat Due to AIDS Drugs: The FDA has approved Egrifta, administered by daily injection,... http://bit.ly/cFaqz3
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
drugs.com — “Egrifta (tesamorelin) is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Includes Egrifta side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 12, 2010 at 1:25 am By:
FDA Approves Egrifta for the Reduction of Excess Abdominal Fat in HIV Patients with Lipodystrophy - http://bit.ly/bYTUCU
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
drugs.com — “Egrifta (tesamorelin) is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Includes Egrifta side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 12, 2010 at 12:10 am By:
Drugs and Devices OW OW Health
FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abd... http://bit.ly/aGIPwA #drug
Theratechnologies stock jumps on FDA approval | Reuters
reuters.com — “* Shares climb 15 percent to C$5.75 * Egrifta approved for HIV-related lipodystrophy * Company to now focus on expanding market outside U.S. TORONTO, Nov 11 (Reuters) - Shares of Theratechnologies ” View full resource at reuters.com
Most Recently Shared on November 11, 2010 at 9:10 pm By:
Theratechnologies stock jumps on FDA approval http://bit.ly/91F2Aw
Egrifta approved for HIV-associated abdominal lipodystrophy - MPR
empr.com — “Merck and EMD Serono announced that the FDA has approved Egrifta (tesamorelin for injection), a growth hormone releasing factor (GRF) analog, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.” View full resource at empr.com
Most Recently Shared on November 11, 2010 at 4:55 pm By:
MPR News: Egrifta approved for HIV-associated abdominal lipodystrophy: Merck and EMD Serono announced that the F... http://bit.ly/ddgVS8
Egrifta approved for HIV-associated abdominal lipodystrophy - ONA
oncologynurseadvisor.com — “Merck and EMD Serono announced that the FDA has approved Egrifta (tesamorelin for injection), a growth hormone releasing factor (GRF) analog, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on November 11, 2010 at 4:18 pm By:
OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education
Egrifta approved for HIV-associated abdominal lipodystrophy http://goo.gl/fb/7J3d9
FDA Approves Egrifta for Treatment of Lipodystrophy in People With HIV - The Body
thebody.com — “On November 10, 2010, the Food and Drug Administration approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which ...” View full resource at thebody.com
Most Recently Shared on November 11, 2010 at 1:01 pm By:
FDA Approves Egrifta for Treatment of Lipodystrophy in People With HIV http://www.thebody.com/content/art59376.html?tw #aids #fat #hump
Advertisement
WebMD_News
@WebMD_News
Egrifta OK’d for Excess Fat Due to AIDS Drugs: The FDA has approved Egrifta, administered by daily injection, fo... http://bit.ly/dw8Z2L
1 year ago...